Jon Macicior
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jon Macicior has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Silvia Ortega-Gutiérrez
Organic Chemistry Department, Faculty of Chemical Sciences, Complutense University of Madrid, Madrid, Spain
3 shared publications Alba García-Martín
Universidad Complutense de Madrid
1 shared publication- Angeles Canales
Department of Organic Chemistry Faculty of Chemistry Universidad Complutense de Madrid Madrid Spain
1 shared publication - Beatriz Marcos-Ramiro
Department of Organic Chemistry School of Chemistry Universidad Complutense de Madrid Plaza de las Ciencias s/n 28040 Madrid Spain
1 shared publication - Beatriz Marcos-Ramiro
Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
1 shared publication Daniel Fernández
Universidad Complutense de Madrid
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria
Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by a mutation in the LMNA gene, leading to the production of progerin, an aberrant and toxic form of lamin A. Due to its hydrophobic nature, progerin accumulates at the nuclear membrane, disrupting nuclear architecture, impairing cellular functions, and ultimately resulting in death around adolescence. Reducing progerin levels is considered the most effective strategy to improve disease progression. To date, small-molecule approaches have primarily targeted progerin upstream mechanisms to indirectly reduce its levels. In this study, we report the development of first-generation proteolysis targeting chimeras (PROTACs) designed to directly degrade progerin, establishing a novel therapeutic paradigm for HGPS. We identify UCM-18142 (compound 2) as the first PROTAC capable of selectively degrading progerin. Treatment with UCM-18142 results in significant improvements in cellular phenotype in both HGPS patient-derived cells and a murine model, including enhanced proliferation, reduced senescence markers, and normalization of nuclear and mitochondrial abnormalities. Additionally, transcriptomic analysis of treated human cells reveals the cellular pathways modulated by compound. Remarkably, PROTAC 2 reduces progerin levels in vivo, supporting the therapeutic potential of this direct-targeting approach and opening new avenues for intervention in HGPS and related laminopathies.
- 22 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessFirst Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria
Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by a mutation in the LMNA gene, leading to the production of progerin, an aberrant and toxic form of lamin A. Due to its hydrophobic nature, progerin accumulates at the nuclear membrane, disrupting nuclear architecture, impairing cellular functions, and ultimately resulting in death around adolescence. Reducing progerin levels is considered the most effective strategy to improve disease progression. To date, small-molecule approaches have primarily targeted progerin upstream mechanisms to indirectly reduce its levels. In this study, we report the development of first-generation proteolysis targeting chimeras (PROTACs) designed to directly degrade progerin, establishing a novel therapeutic paradigm for HGPS. We identify UCM-18142 (compound 2) as the first PROTAC capable of selectively degrading progerin. Treatment with UCM-18142 results in significant improvements in cellular phenotype in both HGPS patient-derived cells and a murine model, including enhanced proliferation, reduced senescence markers, and normalization of nuclear and mitochondrial abnormalities. Additionally, transcriptomic analysis of treated human cells reveals the cellular pathways modulated by compound. Remarkably, PROTAC 2 reduces progerin levels in vivo, supporting the therapeutic potential of this direct-targeting approach and opening new avenues for intervention in HGPS and related laminopathies.
- Open Access
- 3 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7190
Small-Molecule Therapeutic Perspectives for the Treatment of Progeria
Hutchinson–Gilford progeria syndrome (HGPS), or progeria, is an extremely rare disorder that belongs to the class of laminopathies, diseases characterized by alterations in the genes that encode for the lamin proteins or for their associated interacting proteins. In particular, progeria is caused by a point mutation in the gene that codifies for the lamin A gene. This mutation ultimately leads to the biosynthesis of a mutated version of lamin A called progerin, which accumulates abnormally in the nuclear lamina. This accumulation elicits several alterations at the nuclear, cellular, and tissue levels that are phenotypically reflected in a systemic disorder with important alterations, mainly in the cardiovascular system, bones, skin, and overall growth, which results in premature death at an average age of 14.5 years. In 2020, lonafarnib became the first (and only) FDA approved drug for treating progeria. In this context, the present review focuses on the different therapeutic strategies currently under development, with special attention to the new small molecules described in recent years, which may represent the upcoming first-in-class drugs with new mechanisms of action endowed with effectiveness not only to treat but also to cure progeria.
- 3 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7190
Open AccessSmall-Molecule Therapeutic Perspectives for the Treatment of Progeria
Hutchinson–Gilford progeria syndrome (HGPS), or progeria, is an extremely rare disorder that belongs to the class of laminopathies, diseases characterized by alterations in the genes that encode for the lamin proteins or for their associated interacting proteins. In particular, progeria is caused by a point mutation in the gene that codifies for the lamin A gene. This mutation ultimately leads to the biosynthesis of a mutated version of lamin A called progerin, which accumulates abnormally in the nuclear lamina. This accumulation elicits several alterations at the nuclear, cellular, and tissue levels that are phenotypically reflected in a systemic disorder with important alterations, mainly in the cardiovascular system, bones, skin, and overall growth, which results in premature death at an average age of 14.5 years. In 2020, lonafarnib became the first (and only) FDA approved drug for treating progeria. In this context, the present review focuses on the different therapeutic strategies currently under development, with special attention to the new small molecules described in recent years, which may represent the upcoming first-in-class drugs with new mechanisms of action endowed with effectiveness not only to treat but also to cure progeria.
- 23 December 2020
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2021 (9) , 1307-1320
Chemistry for the Identification of Therapeutic Targets: Recent Advances and Future Directions
The increasing availability of chemical probes for specific applications in chemical biology and medicinal chemistry is extensively facilitating our knowledge of biological systems. This understanding has fundamental implications in the development of new efficacious therapeutic strategies. Nowadays, successful drug discovery programs consider identification, engagement, and endogenous levels of the intended therapeutic target from the earliest preclinical stages. All these aspects are addressed with the use of chemical probes, compounds that rely on the use of a particular chemical reaction to give an answer to a specific biological question. In this review we will describe the underlying chemistry and the most recent advances experienced in the field together with their most important biomedical applications.
- 23 December 2020
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2021 (9) , 1307-1320
Chemistry for the Identification of Therapeutic Targets: Recent Advances and Future Directions
The increasing availability of chemical probes for specific applications in chemical biology and medicinal chemistry is extensively facilitating our knowledge of biological systems. This understanding has fundamental implications in the development of new efficacious therapeutic strategies. Nowadays, successful drug discovery programs consider identification, engagement, and endogenous levels of the intended therapeutic target from the earliest preclinical stages. All these aspects are addressed with the use of chemical probes, compounds that rely on the use of a particular chemical reaction to give an answer to a specific biological question. In this review we will describe the underlying chemistry and the most recent advances experienced in the field together with their most important biomedical applications.